Rejection is always out there, but it doesn t have to beat you February 17 2021
I have another the bad-news letters in my newspaper file, but they don t bother me nearly so much as they used to.
If you were raised the way I was, it s quite possible you weren t expected to amount to much. It was made clear as I approached high school graduation that I was not likely to go to college, because (A) I had terrible grades (a 1.75 GPA, which is a high D), and (B) nobody in our family had the money to pay for college.
I should also add here that if my parents were to hear that I was in trouble with a teacher, principal, coach, bus driver or anyone else in any position of authority, their reaction was always, OK, what did you do this time?
Shilpa Medicare fell 1.25% to Rs 424.30, extending losses for third day.
The stock has declined 1.6% in three sessions from its recent closing high of Rs 431 on 10 February 2021.
In the past six months, the stock has declined by 31.99% while the benchmark Sensex has added 37.61% during the same period.
In a BSE filing made during market hours today, Shilpa Medicare announced the launch of Sunitinib capsules, under the brand name SUNISHIL in India. The Sunitinib capsules has been launched in three strengths of 12.5 mg, 25 mg and 50 mg
Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. The drug is indicated for the treatment of G.I. Stromal tumor after disease progression on or intolerance to Imatinib mesylate, advanced Renal Cell Carcinoma, and for the treatment of Unresectable or Metastatic Welldifferentiated Pancreatic Neuroendocrine Tumors with Disease Progression in adults.
Read more about Shilpa Medicare launches Sunitinib Capsules under brand name SINISHIL on Business Standard. Sunitinib malate is a novel oral multi targeted tyrosine kinase inhibitor withantitumor and antiangiogenic activities.